Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Santi Therapeutics is raising $10,000,000.00 in new funding. Sources indicate as part of senior management President, Milind Deshpande played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Santi Therapeutics
Santi Therapeutics is a pharmaceutical company that rationally designs molecular glue for high-value disease targets.

To learn more about Santi Therapeutics, visit http://www.santi-tx.com/

Contact:
Milind Deshpande, President
617-778-2572
https://www.linkedin.com/in/milind-deshpande-phd-4547961b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved